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In a recent issue of Nature Medicine, Nasr et al. show that the effectiveness of all-trans retinoic acid and
arsenic trioxide in acute promyelocytic leukemia is independent of their ability to cause differentiation. Tar-
geted destruction of the PML-RARa oncoprotein appears key to eliminating the cells from which relapse can
arise.In 1987, all-trans retinoic acid (RA) was
reported to induce clinical remissions
in acute promyelocytic leukemia (APL)
(Huang et al., 1987), and it was subse-
quently shown to greatly increase cure
when combined with chemotherapy. The
bone marrow of patients with APL differ-
entiates in response to RA, and it was
believed that the curative effect of RA
reflected the ability of this vitamin A deriv-
ative to cause maturation of leukemic
cells. Since that time, RA treatment of
APL has been described as the first
example of successful differentiation
therapy of a human cancer, and much
effort has gone into developing differenti-
ation therapies for other malignancies.
Recent work by Nasr et al. (2008) seems
to pull the rug out from under these efforts
by suggesting that differentiation does not
in fact underlie the remarkable effective-
ness of RA in APL.
A series of studies published in 1998
compared the PML-RARa fusion common
to APL with the rare and clinically RA-
resistant PLZF-RARa fusion (Grignani
et al., 1998; Guidez et al., 1998; He et al.,
1998; Lin et al., 1998). These studies
showed that pharmacologic doses of RA
could induce release of transcriptional
corepressor complexes, activate tran-
scription, and cause differentiation of cells
expressing PML-RARa, but that RA did
not have these same effects on cells ex-
pressingPLZF-RARabecausePLZF inter-
actionwith corepressorswasnot reversed
by RA. Following these observations, the
widely accepted view of APL pathogen-
esis has been that PML-RARa fusions
repress transcription of genes required
for myeloid differentiation and that RA
has a therapeutic effect by reversing this
repression, thereby stimulating myeloid
maturation (Melnick and Licht, 1999). Therelative importance of transcriptional acti-
vation through PML-RARa versus degra-
dation of PML-RARa permitting gene
expression has been an area of continuing
controversy, but the hypothesis that RA is
effective because it inducesdifferentiation
had moved into the realm of accepted
‘‘fact.’’
The current work by Nasr et al. cracks
open this view of how RA cures APL.
Working with primary cells transduced
with PML-RARa, the authors made the
interesting observation that although RA
caused differentiation and suppressed
myeloid colony formation, when RA was
removed, the cultures retained the ability
to form colonies of immaturemyeloid cells.
To follow up on this observation, the
authors moved to in vivo murine models
of APL and examined how cells able to
transfer disease fromone animal to another
were affected byRA treatment. (In theNasr
et al. manuscript, these cells are referred
to as leukemia-initiating cells or ‘‘LICs’’;
such cells have been given varied
names including ‘‘leukemic stem cells’’
and ‘‘leukemia-repopulating cells.’’) The
authors observed that althoughRA therapy
converted leukemic promyelocytes into
differentiated granulocytes, the LICs per-
sisted, albeit at reduced numbers. Next,
the authors showed that differentiation
could occur without any significant impact
on LICs. LowdosesofRA induceddifferen-
tiation without reducing LICs in the PML-
RARa model, and higher doses of RA
induced differentiation of PLZF-RARa
mouse APL cells despite the clinical inef-
fectiveness of RA in human patients with
the PLZF-RARa fusion and no decrease of
LICs in mice. Thus, differentiation per se
does not correlate with reduction of LICs.
In order to understand how LICs might
be eliminated, Nasr et al. turned to studiesCancer Cof RA in combination with arsenic trioxide
(AS), an agent that, like RA, is selectively
effective for APL treatment. At the cellular
level, AS has been observed to cause
partial differentiation as well as apoptosis
of APL cells; at the molecular level, AS
causes a sumoylation of the PML-RARa
fusion that targets it for ubiquitin-medi-
ated degradation. In both mice and
humans, the combination of RA and AS
causes a rapid disappearance of APL
cells and is frequently curative. The
authors showed that although RA and
AS do not synergize as far as inducing
differentiation, the combination causes
rapid disappearance of LICs. Since RA
and AS synergistically caused degrada-
tion of the PML-RARa fusion, the authors
assessed whether such degradation was
required for the elimination of LICs. Borte-
zomib, a proteasome inhibitor, was given
to mice receiving RA and AS. Although
differentiation of APL cells was robust in
these triply treated mice, bortezomib
blocked PML-RARa degradation and
reversed the curative effect of the RA +
AS combination. As the authors note, bor-
tezomib may influence other pathways in
the cells studied, but their results never-
theless link PML-RARa destruction to
the elimination of LICs. Further experi-
ments exploring the impact of cyclic
AMP on APL response, including the
importance of a site of PKA phosphoryla-
tion within the RARa moiety, provided
additional support for their hypothesis
that PML-RARa degradation, but not
myeloid differentiation, underlies the elim-
ination of LICs.
As illustrated in Table 1, the data of
Nasr et al. can be placed in a broader
context for advancing our understanding
of cure in APL. Although at present, RA +
AS appears to be the most effectiveell 15, January 6, 2009 ª2009 Elsevier Inc. 7
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PreviewsTable 1. Impact of Therapies in Acute Promyelocytic Leukemia
Treatment Effect on PML-RARa
Effect on
Promyelocytes
LIC
Elimination Outcome
RA transactivation > degradation differentiation no relapse
RA + arsenic degradation > transactivation differentiation rapid cure
Liposomal RA transactivation and degradation differentiation slow cure or relapse
RA +
anthracycline
death and
differentiation
slow cure or relapse
Retinoic acid (RA) can induce gene transcription through PML-RARa as well as degradation of this
fusion protein. The relative contributions of these activities to the effects of RA on acute promye-
locytic leukemia have not been clear. This table provides a summary interpretation of data available
from human and mouse studies. The work of Nasr et al. (2008) supports the idea that transactiva-
tion underlies RA-induced differentiation but shows that RA does not eliminate cells from which
relapse can arise (LICs). The curative RA + arsenic combination causes both rapid degradation
of PML-RARa and elimination of LICs. How exposure to persistent high levels of RA, as is possible
with liposomal RA, or therapy with a combination of RA + anthracyclinemay be curative is not clear;
these treatments could act through PML-RARa degradation or might eliminate LICs over time
through alternative mechanisms (see text).treatment for APL, APL can be cured with
other regimens. Liposomal RA can be
curative in human patients with APL
(Tsimberidou et al., 2006). The authors
imply that higher and prolonged plasma
levels of RA may cause a greater catabo-
lism of PML-RARa that effects LIC elimi-
nation, but the possibility that such levels
of RA reduce LICs through transactivation
of target genes is not excluded. How the
combination of anthracycline and RA is
often curative is a question for which
even greater speculation is required. Is it
possible that the combination results in
greater destruction of the PML-RARa
fusion than RA alone? Does RA alter
gene expression in such a way as to
make APL LICs more sensitive to the
chemotherapeutic agent? A larger ques-
tion is how complex curative regimens of
induction, consolidation, and mainte-
nance are able to eventually eradicate all
cancer-repopulating cells despite such
cells persisting after initial therapy.
In the work of Nasr et al., LICs were
studied at a functional level but were not
identified as a population distinct from
the bulk of the leukemic population. The
authors state that such isolation would
facilitate ‘‘elucidation of the actual cellular
basis for LIC clearance,’’ speculating that8 Cancer Cell 15, January 6, 2009 ª2009 ElsLIC clearance may be based on loss of
self-renewal or apoptosis. What are likely
to be features of these LICs? Studies of
human leukemias have suggested that
for many APLs, the LICs might be present
in a myeloid committed rather than a stem
cell compartment. The poor transplant-
ability of human APL cells as xenografts
has hampered progress in identifying the
LICs of human APL, but recent systems
show promise for permitting such studies
(Ishikawa et al., 2007). Some transplant-
ablemouse APLmodels show remarkable
morphologic and immunophenotypic
homogeneity, raising the possibility that
the LICs of APL are cells phenotypically
similar to promyelocytes. Are the LICs of
APL a distinct separable cell type, or
might they be cells at a particular stage
of the cell cycle or localized to a particular
microenvironment?
The work of Nasr et al. further extends
our understanding of retinoids in normal
and malignant hematopoiesis. An under-
appreciated aspect of retinoid signaling
is that retinoids not only are inducers of
myeloid differentiation but also can serve
as critical signals that facilitate self-
renewal of stem cells (Purton et al.,
2006). The particular phenotype of APL
may arise because the RARa fusions ofevier Inc.this leukemia dysregulate both the self-
renewal and differentiative roles of RA
and its receptors.
The discovery of RA and AS as thera-
peutics for APL was based on clinical
observations, not on rational drug design.
Conceptually, the idea that these drugs
work by targeting a critical abnormal
protein for degradation fits well with the
notion that malignancies are dependent
upon their oncogenes. Nevertheless, the
possibility that agents can be discovered
or designed that restore maturation to
immature malignant cells should not be
abandoned, even if the former leader in
differentiation therapy might not be so
grown up after all.
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